386 related articles for article (PubMed ID: 28920960)
1. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Tan DSW; Chong FT; Leong HS; Toh SY; Lau DP; Kwang XL; Zhang X; Sundaram GM; Tan GS; Chang MM; Chua BT; Lim WT; Tan EH; Ang MK; Lim TKH; Sampath P; Chowbay B; Skanderup AJ; DasGupta R; Iyer NG
Nat Med; 2017 Oct; 23(10):1167-1175. PubMed ID: 28920960
[TBL] [Abstract][Full Text] [Related]
2. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
3. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
5. A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Box C; Mendiola M; Gowan S; Box GM; Valenti M; Brandon Ade H; Al-Lazikani B; Rogers SJ; Wilkins A; Harrington KJ; Eccles SA
Eur J Cancer; 2013 Jul; 49(11):2512-21. PubMed ID: 23582742
[TBL] [Abstract][Full Text] [Related]
6. Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
Rogers SJ; Box C; Chambers P; Barbachano Y; Nutting CM; Rhŷs-Evans P; Workman P; Harrington KJ; Eccles SA
J Pathol; 2009 May; 218(1):122-30. PubMed ID: 19197951
[TBL] [Abstract][Full Text] [Related]
7. ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Bill A; Gutierrez A; Kulkarni S; Kemp C; Bonenfant D; Voshol H; Duvvuri U; Gaither LA
Oncotarget; 2015 Apr; 6(11):9173-88. PubMed ID: 25823819
[TBL] [Abstract][Full Text] [Related]
8. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
9. A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC).
Low JL; Lau DP; Zhang X; Kwang XL; Rohatgi N; Chan JV; Chong FT; Wong SQR; Leong HS; Thangavelu MT; Rikka S; Skanderup AMJ; Tan DSW; Periyasamy G; Koh JLY; Iyer NG; DasGupta R
EBioMedicine; 2021 Feb; 64():103220. PubMed ID: 33529999
[TBL] [Abstract][Full Text] [Related]
10. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
[TBL] [Abstract][Full Text] [Related]
11. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Cohen EE; Lingen MW; Martin LE; Harris PL; Brannigan BW; Haserlat SM; Okimoto RA; Sgroi DC; Dahiya S; Muir B; Clark JR; Rocco JW; Vokes EE; Haber DA; Bell DW
Clin Cancer Res; 2005 Nov; 11(22):8105-8. PubMed ID: 16299242
[TBL] [Abstract][Full Text] [Related]
12. Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer.
Hsu DS; Hwang WL; Yuh CH; Chu CH; Ho YH; Chen PB; Lin HS; Lin HK; Wu SP; Lin CY; Hsu WH; Lan HY; Wang HJ; Tai SK; Hung MC; Yang MH
Clin Cancer Res; 2017 Aug; 23(15):4388-4401. PubMed ID: 28196873
[No Abstract] [Full Text] [Related]
13. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
14. Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
Weisheit S; Liebmann C
Cell Signal; 2012 Feb; 24(2):422-434. PubMed ID: 21964064
[TBL] [Abstract][Full Text] [Related]
15. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Lu H; Li X; Lu Y; Qiu S; Fan Z
Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
[TBL] [Abstract][Full Text] [Related]
16. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of long non-coding RNA TP73-AS1 inhibits cell proliferation and induces apoptosis in esophageal squamous cell carcinoma.
Zang W; Wang T; Wang Y; Chen X; Du Y; Sun Q; Li M; Dong Z; Zhao G
Oncotarget; 2016 Apr; 7(15):19960-74. PubMed ID: 26799587
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K
Braig F; Kriegs M; Voigtlaender M; Habel B; Grob T; Biskup K; Blanchard V; Sack M; Thalhammer A; Ben Batalla I; Braren I; Laban S; Danielczyk A; Goletz S; Jakubowicz E; Märkl B; Trepel M; Knecht R; Riecken K; Fehse B; Loges S; Bokemeyer C; Binder M
Cancer Res; 2017 Mar; 77(5):1188-1199. PubMed ID: 28031227
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of lncRNA WWTR1-AS1 associates with tumor aggressiveness and unfavorable survival in head-neck squamous cell carcinoma.
Li J; Li Z; Wu Y; Diao P; Zhang W; Wang Y; Yang J; Cheng J
J Cell Biochem; 2019 Oct; 120(10):18266-18277. PubMed ID: 31172583
[TBL] [Abstract][Full Text] [Related]
20. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]